Pharmaceutical Technology

SEPTEMBER 15, 2022

The top 13 players reported more than 10% revenue growth, with BioNTech (3,834.4%), Moderna (2,199.1%), Pfizer (95.2%) and Regeneron Pharmaceuticals (89.1%) reporting a more than 80% year-on-year (YoY) revenue growth from 2020 to 2021, according to GlobalData’s Pharma Intelligence Centre Companies Database. AbbVie reported a 22.7%

Sales 108

Sales Competition Pharmaceutical Pharmaceutical research 108

pharmaphorum

AUGUST 2, 2022

Roche isn’t the only pharma company looking at subcutaneous checkpoint inhibitors, but the phase 3 readout and a plan to submit the data for approval with regulators including the FDA and EMA puts it among the leaders in the category. Results from a trial in first-line NSCLC are due in early 2023.

Marketing 99

Marketing Competition Patients FDA 99

Pharmaceutical Technology

SEPTEMBER 2, 2022

Since the frontline treatment setting is dominated by these regimens, pharma companies have focused on the development of new drugs in the relapsed/refractory (R/R) setting. The first anti-BCMA product to enter the R/R market was GlaxoSmithKline’s antibody-drug conjugate (ADC) Blenrep (belantamab mafodotin-blmf), gaining FDA approval in 2020.

Food and Drug Administration 59

Food and Drug Administration FDA Sales Physicians 59

pharmaphorum

AUGUST 8, 2022

billion in 2028 – a leap forward from the $195 million it made last year and $127 million in the first half of 2022. billion acquisition of Arena Pharma , bringing on board etrasimod in late-stage testing for ulcerative colitis, and made an $11.6 $PFE $GBT [link] pic.twitter.com/52AMCbvFHF.

Marketing 102

Marketing Sales Pharma FDA 102

Pharmaceutical Technology

JANUARY 19, 2023

However, it is possible to target CD33 in the clinic, as evidenced by the FDA approval of Pfizer’s anti-CD33 antibody-drug conjugate Mylotarg (gemtuzumab ozogamicin) in 2000. GlobalData’s Pharma Intelligence Center shows 19 autologous CAR-T cell products in Phase I, and nine products in Phase II, globally.

Marketing 52

Marketing FDA Sales Management 52

Pharmaceutical Technology

JULY 12, 2022

The success of chimeric antigen receptor T-cells (CAR-T) in blood cancers has led to the US Food and Drug Administration's (FDA) approval of six products with a pipeline of cell therapies that numbers in the thousands. The total market for cell therapies in oncology is projected to exceed $37bn worldwide by 2028.

Leads 52

Leads Food and Drug Administration Marketing Sales 52

PM360

SEPTEMBER 21, 2023

In March, the FDA approved several new naloxone products using the pathway, including one from Amphastar, which will compete with other intranasal on the market. The product, manufactured by ARS Pharma and Neurelis Pharma, would be the first needle-free epinephrine alternative to autoinjectors, such as the EpiPen.

Management 105

Management Manufacturing Sales Competition 105

Contrarian Sales Techniques

FEBRUARY 10, 2023

According to various market research reports, the global non-invasive medical devices market was valued at approximately USD 45 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of over 6% from 2021 to 2028. This growth is driven by several factors, including: 1.

Healthcare 52

Healthcare Healthcare Manufacturing Medical 52

pharmaphorum

OCTOBER 18, 2022

Akouos has a portfolio of experimental gene therapies led by AK-OTOF, which uses an adeno-associated virus (AAV) vector to a functional copy of the otoferlin (OTOF) gene and was recently approved for clinical testing by the FDA. per month if conditions are not met, until the end of 2028 when they will all expire.

Medicine 52

Medicine FDA Patients Pharma 52